Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Asymptomatic HIV-1-infected individuals who are treatment-experienced and who have not been on ART for at least 16 weeks.~* Have documented prior non-suppressive ART including at least 1 NRTI, 1 NNRTI and 2 PIs; or have documented prior ART resistance to at least 1 NRTI, 1 NNRTI and 1 PI; AND in the opinion of the investigator, have few, if any, effective treatment options available.~* Have \>2,500 copies/mL of HIV-1 RNA at screening.~* Have a stable CD4 cell count while off ART and \>250 cells/mL at screening.~* Have no clinically significant findings on screening evaluations.~Exclusion Criteria:~* Have a current or recent opportunistic infection that, in the opinion of the investigator, is not being controlled by medication.~* Have any condition that, in the opinion of the investigator, could compromise subject safety or adherence to the protocol.~* Have a documented positive test for hepatitis B surface antigen, or have received any antiviral therapy for hepatitis C \<6 weeks prior to study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).